Results 71 to 80 of about 193,970 (395)
Biliary tract cancer patient-derived xenografts: Surgeon impact on individualized medicine
Background & Aims: Biliary tract tumors are uncommon but highly aggressive malignancies with poor survival outcomes. Due to their low incidence, research into effective therapeutics has been limited.
Jennifer L. Leiting +16 more
doaj +1 more source
Topoisomerase expression and amplification in solid tumours: Analysis of 24,262 patients. [PDF]
BackgroundTopoisomerase I (TOPO1) and topoisomerase IIα (TOP2A) are specific targets of multiple chemotherapy drugs. Increased expression of TOPO1 protein and amplification of the TOP2A gene have been associated with treatment response in colorectal and ...
Arguello, David +4 more
core +1 more source
Strategies to Improve the Lipophilicity of Hydrophilic Macromolecular Drugs
Hydrophilic macromolecular drugs can be successfully lipidized by covalent attachment of lipids, by hydrophobic ion pairing with negatively or positively charged surfactants, and by dry or wet reverse micelle formation. Lipophilicity enhancement of hydrophilic macromolecules has several benefits including stability and bioavailability improvement ...
Sera Lindner +8 more
wiley +1 more source
Occurrence of pancreatic, biliary tract, and gallbladder cancers in Alaska Native people, 1973–2007 [PDF]
Objectives: To describe the occurrence of pancreatic, biliary tract, and gallbladder cancers within the Alaska Native (AN) population. Study design: Population-based analysis utilizing a tumor registry and comparative population data.
Steven R. Alberts +3 more
doaj +1 more source
Chemotherapy for Biliary Tract Cancer
The term of biliary tract cancer (BTC) refers to all tumors that arise from the biliary tract or the biliary drainage system, including the intra- and extra-hepatic bile ducts as well as the gallbladder. BTCs are aggressive tumors with limited treatment options and poor overall survival.
openaire +3 more sources
Genomic alterations in biliary tract cancer predict prognosis and immunotherapy outcomes
Background Recently, immunotherapy with immune checkpoint inhibitors (ICIs) has shown promising efficacy in biliary tract cancer (BTC), which includes gallbladder cancer (GBC) and cholangiocarcinoma (CHOL).
Xiaofeng Chen +21 more
semanticscholar +1 more source
Probiotic‐Based Materials as Living Therapeutics
Recent advances in Engineered Living Materials are highlighted, integrating synthetic biology and advanced materials, with a focus on probiotic‐based therapeutics. Probiotic Living Materials hold great potential for biosensing, infection treatment, osteogenesis, wound healing, vaginal and gastrointestinal disorders, and cancer therapy. breakthroughs in
Laura Sabio +2 more
wiley +1 more source
Recommendations for clinical and molecular identification of LS, surgical and endoscopic management of LS‐associated colorectal cancer and preventive measures for cancer were produced. The emphasis was on surgical and gastroenterological aspects of the cancer spectrum.
T. T. Seppälä +18 more
wiley +1 more source
Hepatocellular carcinoma (HCC) is the global leading cause of cancer-related deaths due to the deficiency of targets for precision therapy. A new modality of epigenetic regulation has emerged involving RNA–RNA crosstalk networks where two or more ...
Yanping Wei +17 more
doaj +1 more source
Immunotherapy of biliary tract cancer
Biliary tract cancers (BTCs), which encompass intra- and extrahepatic cholangiocarcinomas as well as gallbladder carcinomas, are one of the most aggressive malignancies. Although the development of systemic chemotherapy approaches has made progress, the prognosis of BTC remains poor. Chronic inflammation plays an important role in the carcinogenesis of
openaire +2 more sources

